AiLNP

AiRNA

AiTEM

AI驱动`药物递送`和`药物发现`

AI-Driven `Drug Delivery` and `Drug Discovery`

&quot;Humanity has never ceased in its pursuit of technology, and in turn, the advance of science and technology has also pushed the boundaries of business and reshaped our society. Today, we are witnessing an overwhelming emergence of new technologies, including artificial intelligence, quantum computing, chip manufacturing, medical biology, and controllable nuclear fusion, many of which are on their cusp of explosive growth. Meanwhile, amidst the hustle and bustle of scientific and technological progress, we need to understand: What kind of huge changes or impacts will technology bring to human beings? What kind of guidelines do pioneers who master cutting-edge technologies need to adhere to, to ensure that new technologies can promote the continued prosperity and development of mankind?”On March 30, the 2023 Fortune Global Tech Forum was held in Guangzhou. The Fortune Global Tech Forum is an annual international technology event hosted by Fortune. The event brings together executives from leading global companies, scholars who are at the forefront of technological progress in their respective fields, high-profile technology entrepreneurs, and well-known technology investors to share insights and forecast trends on hot topics such as the computing power economy, ChatGPT, electric vehicles, carbon neutrality, the digital economy, chip manufacturing, healthcare, and artificial intelligence.The forum&#x27;s theme is &quot;New Frontiers: Change and Resilience&quot; , which highlights the important trends in the global technology industry. This forum provides a unique opportunity for business executives, entrepreneurs, and investors to engage with the leaders of the digital revolution and discuss how to shape the future world.Dr.Wenshou Wang, the co-founder and COO of METiS Pharmaceuticals, was honored to represent METiS Pharmaceuticals upon the invitation to attend the Forum, and in the sub-forum titled &quot;the Future of Healthcare,&quot; Dr. Wang joined Clay Chandler, the executive editor for Asia at Fortune, Cheryl Cui, the co-founder and CEO of Bota Bio, Shuhao Wen, the co-founder and president of XtalPi Inc., and Huanqing Gu, the founder and president of the Stemcell United Ltd.(SCU), to discuss how innovative technologies can empower and enhance healthcare, and explore the cutting-edge new trends, in the context of the rapid development of science and technology.Dr. Wang remarked that the development of new drugs is becoming increasingly time-consuming and costly at present. He asserted that AI technology will revolutionize the pharmaceutical industry by automating the drug development process and making it more effective. “Rather than relying on blind trial-and-error methods, AI can provide a more purposeful approach to drug development, reducing the need for trial and error. Additionally, automating the manual tasks will significantly improve research and development efficiency.’’ he further explained. <div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/5450dc113804b2362d895fdc6d3f9f22.jpg" width="718.667px" height="478px" style="width:718.667px;height:478px"/></div><div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/47198948d72248feb51b321a310283e5.jpg" width="718px" height="474px" style="width:718px;height:474px"/></div>Dr. Wenshou Wang, the co-founder and COO of METiS Pharmaceuticals, sharing his insights at the forum&quot;AI + drug delivery&quot; technology will overcome the technological bottlenecks of conventional drug R&amp;D, and are poised to become the key to developing a new generation of treatment for the future, exemplified RNA therapeutics. The technology refers to the precise delivery of drugs and gene therapies to target organs, tissues and cells to cure diseases. On the other hand, in the development of new small molecule drugs, drug delivery technology can also improve pharmaceutical preparations/formulations of existing drugs, so as to develop new small molecule drugs with lower toxicity and better efficacy in a faster and more efficient manner. METiS is pushing the boundaries of drugs with the world&#x27;s leading technology platform for targeted drug delivery, which has diverse application potentials and offers excellent market prospects. About FORTUNEFortune is a globally influential business media organization that focuses on reporting on the ever-changing business landscape. It is renowned for its well-respected lists, such as the Fortune Global 500.Fortune has the unparalleled capability and influence to bring together top business leaders, opinion leaders, policymakers, and experts from various industries. From exclusive dinners to large-scale business and financial conferences, Fortune&#x27;s events are meticulously planned and executed to ensure the utmost quality. Renowned economists and CEOs of multinational corporations participate in these gatherings to discuss innovative technologies and cutting-edge industries, as well as hot issues related to corporate development. By fostering the consensus and foresight, these events help to expand the influence of the host cities, and enable the participants to work together towards extraordinary achievements. Leveraging its strategic focuses, high-level cross-industry interactions, and insights from a professional editorial team, Fortune offers exciting conferences and innovative activities.About METiS（METiS Pharmaceuticals）METiS is an innovative biotechnology company driven by artificial intelligence (AI) that harnesses targeted drug delivery technology to develop more effective drugs for patients. Through the integration of cutting-edge AI technology and traditional pharmaceutical R&amp;D, METiS aims to accelerate the R&amp;D of innovative drugs in a more efficient and precise way, while leveraging the core technology platforms to support the entire pharmaceutical ecosystem and lead industry innovation. Note: Part of the content and pictures come from www.fortunechina.com

共同探讨在科技飞速发展的背景下，创新技术如何赋能和助力医疗健康及未来健康的前沿新趋势

To discuss how innovative technologies can empower and enhance healthcare, and explore the cutting-edge new trends, in the context of the rapid development of science and technology.

剂泰医药受邀出席2023年《财富》全球科技论坛，共话未来健康前沿趋势

METiS Attends 2023 Fortune Global Tech Forum, Sharing Insights on Future Health Trends

<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/c55703a5ed917fcd1ac20a2960c5af8b.jpg" width="656.667px" height="437px" style="width:656.667px;height:437px"/></div>At the beginning of the year of rabbit on January 9, 2023, METiS held the housewarming ceremony at Haiwei Center (Binjiang,Hangzhou) where its new office site located. More than 50 invited guests gathered at the venue, including government officers, investors and partners. Ms. She Jian, Deputy Head of Binjiang District, Mr. Wu Yibo, representative of investors, and Dr. Tang Qiusong, director of Roche Accelerator(China), delivered electric speeches.The newly-built site covers about 5,700 square meters, of which 3,000 square meters are laboratories, including a 1,500 square meter biological laboratory with class C and D clean rooms, which will enable the design, synthesis, purification of mRNA, LNP manufacturing process development, high-throughput cell efficacy evaluation, etc. The 1,500 square meter chemistry laboratory encompasses high-throughput formulation equipment, multi-dosage small molecule new drug development equipment, analysis laboratory, etc., which can be leveraged to achieve the R&amp;D of small molecule new drug formulation and process development, analytical method development and validation of small molecule &amp; mRNA drug, and it also paves the road for the end-to-end preclinical development capability of small molecule and mRNA drugs.<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/fef8fbef599129eb8385e115b4520a88.png" width="961px" height="672px" style="width:961px;height:672px"/></div>She Jian, deputy head of Binjiang District, said, &quot;As a strategic emerging industry that Hangzhou government strives to forge, biomedicine has been recognized as imperative. Today, some young enterprises like METiS Pharmaceutical has brought new momentum to China and even the world&#x27;s biomedicine. We hope that in the future, METiS can get the utmost out of the advantages of technology platform and talent platform, and collaborate with pharmaceutical enterprises in Hangzhou to bolster the pharmaceutical industry in Hangzhou to be bigger and stronger. The district government will also continue to propell the development of enterprises and provide assistance within its capacity.&quot;Dr. Tang Qiusong, director of Roche Accelerator(China), said,&quot; The fruitful collaboration between China Roche Accelerator and METiS Pharmaceutical has proved that the cooperation and exchanges between emerging companies and large pharmaceutical companies can facilitate the advancement of research and development projects, which shed light on the significant value of business cooperation model. Roche sincerely hopes that METiS will expedite its development of the collaborated ‘delivery system project’ for a big leap into the rosy bio-ocean.&quot;Caida Lai, Ph.D., co-founder &amp;CEO of METiS, said, &quot; METiS has been pushing the envelope for years, and we have turned the tide of technology in 2022. Hundreds of LNP with proprietary right and breakthrough technology are generated from our cutting-edge AiLNP delivery Platform, which already created billion dollars of high-net-worth value. And we are looking forward to some more massive collaborations. We have successfully developed multi-organ targeted delivery, such as liver, lung, CNS and tumor tissues, and achieved long-term release in local site. These technological breakthroughs open huge opportunities for unmet clinical needs of human beings such as cancer and neurological diseases.&quot;In 2022, we upgraded from a technology platform to a product platform. We are developing new modality formulations and a number of breakthrough small molecule reformulations benefiting from AiTEM platform’s technology. MTS004 is expected to start phase III in the first half of this year. MTS004 can treat Pseudobulbar affect, which affects millions of cerebral stroke patients, Parkinson patients and other patients in China. METiS will bring the first therapeutic drug for this indication in China to meet the huge clinical demand. In addition, we have generated billion dollars value in pipeline by developing blockbuster drugs in some complex formulations, the worth-mentioning long-acting oral sustained-release that address critical pain points, such gastrointestinal adverse reactions, toxicity reduction, and efficacy synergism in multiple tumors and rare diseases.&quot;The &quot;AI+ Drug Delivery and Discovery&quot; seminar was held in the afternoon. Several R&amp;D execs shared wonderful technologies from the perspective of high-throughput formulation development, long-acting formulation development, LNP design, mRNA design, quantum computing, artificial intelligence AI algorithm and so on. At the same time, homing in on &quot;RNA and gene therapy industry opportunities and challenges, application scenarios, strategy deployment and corner overtaking opportunities&quot;, Dr. Caida Lai held a round-table discussion with Guo Xiaodi, Chief scientist and Director of Pharmaceutical Research Institute of Huahai Pharmaceutical, Haijun Yu, Researcher of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Yun Yang, co-founder and CFO of Circode Biology, and Wang Kai, Researcher of School of Basic Medical science, Peking University. Universal recognition has been given to the huge development prospect of RNA and gene drugs in the future, as well as the potential of AI enabling RNA, gene drugs R&amp;D and its optimization.<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/02db89967e9dd0c20d9d48f7fa511f07.png" width="671.6666870117188" height="454" style="width:671.6666870117188px;height:454px"/></div>Since its inception, METiS has always been clinical demand-oriented, exploring the path of artificial intelligence-driven drug delivery and drug discovery innovation, and achieving many technological breakthroughs and application expansion. The commissioning of the new site is an great leap in the company&#x27;s continued exploration and expansion in the field of drug development and delivery. Ring in the new and look to the future. In 2023, METiS will continue to achieve new technological breakthroughs, optimize the technology platform, and strive to advance to the blue ocean of &quot;AI+ drug delivery and discovery&quot; with the support and company from many others.

辞旧迎新，展望未来。剂泰医药在2023年还将继续实现新的技术突破，优化技术平台，在多方的支持与陪伴下向「AI+药物递送与发现」蓝海不断进发！

Ring in the new and look to the future. In 2023, METiS will continue to achieve new technological breakthroughs, optimize the technology platform, and strive to advance to the blue ocean of "

剂泰医药乔迁仪式暨「AI+药物递送与发现」专题研讨会圆满举行

METiS Held the ‘AI+ Drug Delivery & Drug Discovery’ Seminar & the Housewarming Ceremony

Recently, Small and Medium Enterprise Administration, directed by Ministry of Industry and Information Technology has released the top 500 list in the 7th ‘MAKER IN CHINA’ contest. The contest has covered 35 regional competitions, 6 industrial chain collaboration competitions, 5 specific competitions in key industries, and 1 oversea competition. More than 37,000 SMEs were signed up, and it is an increase of 18% on a YOY basis.Not long ago in June of the same year, METiS participated in the &quot;Maker Beijing 2022&quot; contest which was jointly sponsored by the Municipal Bureau of Economy and Information Technology, the Municipal Bureau of Finance, and the People&#x27;s Government of Fengtai District of Beijing. Dr. Caida Lai, CEO, and Dr. Andong Liu, VP of Innovative Technology participated in the competition. METiS’s project named as &quot;Driving Drug Delivery Development&quot; was awarded as a TOP150 project. As the winning project of Beijing Regional Competition, METiS was successfully recommended by the competent authorities to participate in the &quot;Maker China&quot; SME Innovation and Entrepreneurship Contest. Finally, it set apart from 150 high-quality projects and was honored as the top 500 with a pass through the public notification period.<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/61b6b3c7291bec902fccef47c46cd8cc.jpg" width="620px" height="797px" style="width:620px;height:797px"/></div>From ‘MAKER IN CHINA’ Official WebsiteMAKER in BEIJING 2022‘MAKER in BEIJING 2022’ Innovation and Entrepreneurship Contest was jointly sponsored by the Municipal Bureau of Economy and Information Technology, the Municipal Bureau of Finance, and the People&#x27;s Government of Fengtai District of Beijing. The contest covers Regional Chapters and Leading Cooperates Competitions, and it is based on the theme of ‘Maker in Beijing, Intelligence for Future’.  The contest aiming at taking the regional advantage of Beijing as a center of science and technology Innovation to push the envelope to against the risks of pandemic, economy &amp;employment slump and stagnant development, and to create a broad platform for small and medium-sized enterprises and makers to exchanging ideas, collaboration, projects incubation. It is endeavored to beef up the industrial ecology of collaborative innovation, resource sharing and integrated development between large enterprises and small and medium-sized enterprises.About ‘MAKER IN CHINA’ SMES ContestThe &quot;Maker in China&quot; SME Innovation and Entrepreneurship Contest was jointly organized by the Ministry of Industry and Information Technology and the Ministry of Finance, is aiming at motivating innovation, aggregating entrepreneurship resources, building innovative entrepreneurial climate, and developing a platform for small and medium-sized enterprises (SMEs) to exchanging ideas, collaboration, projects incubation. The contest is also aiming at discovering and fostering a number of outstanding projects, creating new products, new technology, new pattern and new industrial form, facilitating the transformation and upgrading of small and medium-sized enterprises to be more professional, refined, specialized and innovative, driving integrated innovation among large, small and medium-sized enterprises, and bolstering manufacturing power and cyber power of China.About METiSMETiS Pharmaceuticals is a biotechnology company that aims to address unmet clinical needs by integrating drug delivery and drug discovery with artificial intelligence, machine learning and quantum simulation to find optimal therapies across a broad spectrum of disease areas. Business Collaboration<a href="mailto:sarenty@metispharmaceuticals.com">sarenty@metispharmaceuticals.com</a> Media<a href="mailto:pr@metispharmaceuticals.com">pr@metispharmaceuticals.com</a>

剂泰医药参赛项目作为北京区域赛获奖项目，顺利获得主管部门推荐，参与到此次“创客中国”中小企业创新创业大赛当中，最终从150个优质项目中脱颖而出，荣幸获选大赛500强，并通过了公示期。

METiS was successfully recommended by the competent authorities to participate in the "Maker China" SME Innovation and Entrepreneurship Contest. Finally, it set apart from 150 high-quality pr

剂泰医药获选“创客中国”中小企业创新创业大赛500强

METiS Got Tapped as Top 500 SME Innovation and Entrepreneurship Contest by ‘MAKER IN CHINA’

The Hurun Research Institute recently released the Hurun Global Gazelle Index 2022 Half-Year Report. Out of many biotech companies, METiS found a remarkable spot in the list.<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/c5c3f436ab1ecbf849bc43d5ae3190c1.jpg" width="670" height="297" style="width:670px;height:297px"/></div>The report listed companies founded after 2000, with high growth potential of US$1bn valuation mark within 3 years, which are most likely to ‘go unicorn’. The valuation of the listed Gazelles ranging from US$ 500mn to US$ 1 Bn. Hurun Research has been tracking Unicorns since 2017 and Gazelles since 2018. This is the second edition of the Hurun Global Gazelle Index.Hurun Research found 621 Gazelles in the world, based in 33 countries and 151 cities. On average, they were set up in 2015, 74% of them selling software and services and only 26% selling physical products. 58% are selling to businesses, whilst 42% are consumer-facing. Gazelles were disrupting healthcare, financial services and business management solutions.full list at：https://mp.weixin.qq.com/s/8qSt5QEJIFSMCzDKOr2qzg

《2022年中胡润全球瞪羚企业》列出了成立于2000年之后、三年内最有可能达到独角兽级十亿美金估值的高成长性企业。

The report listed companies founded after 2000, with high growth potential of US$1bn valuation mark within 3 years, which are most likely to ‘go unicorn’. 

剂泰医药荣登胡润研究院《2022年中胡润全球瞪羚企业》

METiS Got Recognized in Hurun Global Gazelle Index 2022 Half-Year Report

剂泰医药（METiS）是全球首家以人工智能驱动药物递送和药物发现的生物技术公司，集合人工智能、机器学习和量子模拟等先进技术，旨在实现更有效的创新递送材料设计、候选药物选择和制剂设计、“可编程核酸药物”开发与核酸递送设计。

核心技术

业务|Business

管线|Pipeline

剂泰医药受邀出席2023年《财富》全球科技论坛，共话未来健康前沿趋势

剂泰医药乔迁仪式暨「AI+药物递送与发现」专题研讨会圆满举行

剂泰医药获选“创客中国”中小企业创新创业大赛500强

剂泰医药荣登胡润研究院《2022年中胡润全球瞪羚企业》